Nuvalent’s stock jumps 22% after ESMO 2024 – what’s next for this biotech game-changer?

Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the release of compelling data from two clinical ... Read More